NBIX biotech catalysts & pipeline

NEUROCRINE BIOSCIENCES INC · Data as of 2026-10-25

Upcoming catalysts

direclidine — Topline data

2027

We have initiated a comprehensive Phase 3 clinical program for direclidine in schizophrenia (with initial topline data expected in 2027), including studies evaluating efficacy in patients experiencing an acute relapse of schizophrenia and long-term safety.

Source filing

osavampator — Topline data

2027

We have initiated a comprehensive Phase 3 clinical program for osavampator in MDD (with initial topline data expected in 2027), including three acute randomized, double‑blind, placebo‑controlled studies, a randomized‑withdrawal maintenance‑of‑effect study, and a long‑term open‑label safety extension, reflecting our confidence in osavampator's potential to elevate the standard of care in MDD.

Source filing

Explore the free biotech catalyst calendar